Congratulations to the new CEO Nicola Caronzolo



MENDRISIO, Switzerland, November 12, 2021 – Today Sintetica SA is celebrating its one hundredth anniversary with events that project the company into the future.

  • An important step in building the future of Sintetica
  • New corporate design builds on company’s strong historical roots
  • Leading representatives from scientific and institutional fields to join the celebration
The celebrations, taking place in the morning and evening, will be attended by important representatives from the worlds of science, academics, and public institutions.

Christian Vitta, State Councilor and Director of the Canton's Department of Finance and Economy, and Raffaele De Rosa, Director of the Department of Health and Social Affairs and State Councilor, will be present.

Co-director of the Department of Physiology and Cellular Biophysics at Columbia University Prof. Filippo Mancia and Prof. Dr. med. Alain Borgeat, Director of the Department of Anesthesiology at Balgrist Orthopedic University Hospital in Zurich, will join an esteemed group of international guests for a scientific symposium titled "The Molecules of Life".

Together with Fondazione AGIRE and Università della Svizzera Italiana, Sintetica will also present the first-ever Sintetica Innovation Award to a winning startup in a competition that was created to recognize promising and innovative Swiss start-ups in the fields of healthcare and life sciences.

The celebrations mark an important step for Sintetica. Unveiling an updated mission statement, Sintetica will reaffirm its commitment to improving therapies based on clinicians' insights to improve patients' lives. This commitment continues in the direction of caring for people's well-being, as well as maintaining strong connections with the Swiss territory and hospitals. A new visual identity, which will be unveiled as part of the celebrations, will express this commitment visually in form of a refreshed logo and corporate design, which build on the company's strong historical roots to project Sintetica into the future. The new look and feel will be implemented gradually across all touchpoints in a phased approach.

"I am excited and honored to welcome our distinguished guests to today's Century Celebration, and equally pleased and proud be joined by the winners and finalists of our first-ever Innovation Award at this wonderful event," said Dr. Miro Venturi, CEO of Sintetica SA. “With our refreshed visual identity, we celebrate our history, expand our horizons and prepare Sintetica for another century of improving patients’ lives."
<- Close

Sintetica Appoints Chief Commercial Officer


Jamie Sparrow appointed Chief Commercial Officer

We are very pleased to announce the appointment of Jamie Sparrow to the newly created position as Chief Commercial Officer, effective August 16, 2021. Reporting to CEO Dr. Miro Venturi, Mr. Sparrow will be responsible for global commercial strategy and execution in this newly created position.
About Mr. Sparrow
A highly professional and entrepreneurial executive, Mr. Sparrow joins us from Glenmark, a global innovative pharmaceutical company based in Mumbai, where he most recently led commercial strategy and operations as Senior Vice President and Head of Europe. In a career spanning more than 30 years, Mr. Sparrow has held senior leadership roles with Arrow Generics, Watson Pharmaceuticals, Actavis and Mylan. Mr. Sparrow brings several key competencies to Sintetica, including business development, sales and marketing and strong general management, acquired in international and regional roles. He has a track record of delivering on demanding business targets, including full country/regional profit and loss responsibilities, focusing on establishing a “win-win” approach with colleagues, customers, suppliers and other key stakeholders.

About Sintetica
As we explore ways to bring better products to patients and HCPs faster, Mr. Sparrow’s broad commercial expertise will play a key role in evolving the business strategically as well as identifying and quickly seizing market opportunities as they emerge.
Looking back at 100 years of history and with roots in Switzerland, we are embarking on a new phase of accelerated international growth. As a leading supplier of analgesics, local anesthetics and sterile injectable solutions in ampoules, vials and IV bags for hospitals, we develop and deliver products that are differentiated from traditional generic medicines and increase patient safety as well as convenience for the HCPs that administer these products. Our products are sold through sales subsidiaries in selected European markets and through partnerships with leading distributors around the world.
We welcome Mr. Sparrow to Sintetica and wish him great success!
<- Close

Harrow Health Acquires Patented Ophthalmic Surgical Drug Candidate from Sintetica


New Drug Application Expected to Be Filed in Late 2021

Harrow Health, Inc. (Nasdaq: HROW), an ophthalmic‑focused healthcare company, today announced that it has entered into an agreement with Sintetica, S.A., a growing pharmaceutical company focused on analgesics, local anesthetics and sterile injectable solutions, to acquire the marketing and supply rights in the U.S. and Canada for AMP‑100, a patented ophthalmic surgical drug candidate. When approved, AMP-100 will provide ocular surface anesthesia during ophthalmic interventions such as cataract surgery and intravitreal injections, which are estimated to total over 10 million procedures annually in the U.S.(1)
Harrow Health, Inc. (Nasdaq: HROW), an ophthalmic‑focused healthcare company, today announced that it has entered into an agreement with Sintetica, S.A., a growing pharmaceutical company focused on analgesics, local anesthetics and sterile injectable solutions, to acquire the marketing and supply rights in the U.S. and Canada for AMP‑100, a patented ophthalmic surgical drug candidate. When approved, AMP-100 will provide ocular surface anesthesia during ophthalmic interventions such as cataract surgery and intravitreal injections, which are estimated to total over 10 million procedures annually in the U.S.(1)
AMP-100 is a patented, innovative ocular surface anesthetic drug candidate, with safety and efficacy supported by a robust pre-clinical and clinical program, including a recently completed Phase 3 study that successfully compared the efficacy and tolerability of AMP-100 to current standards of care. Sintetica intends to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in late 2021. When approved, the active ingredient used in AMP-100 will be the first approved use of this active ingredient in the U.S. ophthalmic market. 
Commenting on the acquisition, Mark L. Baum, CEO of Harrow Health, said, “This transaction reflects Harrow Health’s commitment to continued growth by adding new high-value products to our portfolio. The acquisition of rights to market and sell AMP-100 in the U.S. and Canada will further fortify our greatest commercial strength – providing thousands of U.S. eyecare professionals and their patients with novel ophthalmic surgical products. When approved, we expect to fully leverage our wholly owned, efficient, scalable, and tech-enabled ImprimisRx ophthalmic-focused commercial and distribution platform to market AMP-100 to our ‘front-of-the-eye-focused’ customer base, such as cataract and refractive surgeons. In addition, we intend to invest in expanding our commercial footprint to include retina-focused surgeons to fully leverage the market potential of AMP-100.”
“We have a sound business strategy for commercializing our promising and innovative products in countries around the world,” added Miro Venturi, Corporate CEO for Sintetica, S.A. “We are convinced that Harrow Health, with its knowledge and expertise in ophthalmology and commitment to providing high‑quality medications, is the optimal choice for Sintetica to partner with to bring AMP‑100 to the U.S. market.”

Under the terms of the agreement, Sintetica will be responsible for regulatory filings for the product in the U.S. The agreement provides for upfront and milestone payments to Sintetica as well as per unit royalties on sales of AMP-100, when successfully commercializedHarrow Health will have marketing rights for the U.S. and Canada, while Sintetica will retain the marketing rights in other countries.
B. Riley Securities acted as financial advisors to Harrow Health for the transaction.
About Sintetica
Based in Mendrisio, Switzerland, Sintetica is a growing privately held international pharmaceutical company focused on analgesics, local anesthetics and sterile injectable solutions in ampoules, vials and IV bags for hospitals. Sintetica develops medicines in concentrated and premixed formulations, which enables healthcare practitioners to administer these products without manipulation and dilution, increasing patient safety and improving convenience for patients and HCPs. Sintetica runs sales subsidiaries in selected European markets and partners with leading distributors around the world. In 2020, Sintetica employed 277 employees and produced 52.9 million products, with revenues of close to CHF 90 million. For more information about Sintetica, please visit the corporate website,
About Harrow Health
Harrow Health, Inc. (NASDAQ: HROW) is an ophthalmic-focused healthcare company. The Company owns and operates ImprimisRx, one the nation’s leading ophthalmology-focused pharmaceutical businesses, and Visionology, a direct-to-consumer eye care subsidiary focused on chronic eye disease. Harrow Health also holds equity positions in Eton Pharmaceuticals, Surface Ophthalmics and Melt Pharmaceuticals, all of which started as Harrow Health subsidiaries. Harrow Health also owns royalty rights in four clinical stage drug candidates being developed by Surface Ophthalmics and Melt Pharmaceuticals. For more information about Harrow Health, please visit the Investors section of the corporate website,
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such “forward-looking statements.” Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties which may cause results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include the impact of the COVID-19 pandemic and any future health epidemics on our financial condition, liquidity and results of operations; our ability to make commercially available our compounded formulations and technologies in a timely manner or at all; market acceptance of the Company’s formulations and challenges related to the marketing of the Company’s formulations; risks related to our compounding pharmacy operations; our ability to enter into other strategic alliances, including arrangements with pharmacies, physicians and healthcare organizations for the development and distribution of our formulations; our ability to obtain intellectual property protection for our assets; our ability to accurately estimate our expenses and cash burn, and raise additional funds when necessary; risks related to research and development activities; the projected size of the potential market for our technologies and formulations; unexpected new data, safety and technical issues; regulatory and market developments impacting compounding pharmacies, outsourcing facilities and the pharmaceutical industry; competition; and market conditions. These and additional risks and uncertainties are more fully described in Harrow Health’s filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Such documents may be read free of charge on the SEC's web site at Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. Except as required by law, Harrow Health undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.


For Sintetica:
Daniel Braxton
Head Branding & Communications
+41 79 514 94 97

For Harrow:
Jamie Webb, Director of Communications and IR

(1) Market Scope 2019, IOL Market Report, April 2019, and Ophthalmologica,
2018 Update on Intravitreal Injections, accessed 7/27/21
<- Close

We are delighted to announce that Miro Venturi is our new Corporate CEO. Welcome aboard Miro!

Miro has received a combined humanistic and scientific education by first attending the Liceo Linguistico in Faenza and later studying chemistry and biology at the University of Bologna, where he received his first degree in Biology and Biochemistry.

After that, Miro earned his Doctorate (PhD) in Biophysics at the Max-Planck Institute of Frankfurt/Main, Germany, (in the Team of Nobel laureate Prof. Dr. Hartmut Michel) and later a postdoctoral specialization in Molecular Medicine at the National Institutes of Health in Bethesda, Maryland, under the US Government sponsorship.

His scientific work lead to several patents and has been published in more than 60 peer-reviewed inter­national articles and internationally cited across the academic and industrial communities.

Miro joined the pharmaceutical industry in 2000, driven by the desire to apply science for the benefits of patients: he has built translational sciences and patients’ focused drug development organizations across a range of therapeutic areas, always with an emphasis in helping to globally scale biomarker-driven drug development, and realize the promise of precision medicine and person­alized therapies.

This work has helped Roche Pharmaceuticals to significantly streamline, accelerate and improve drug development and pipeline activity, leading to the successful market launch of numerous blockbuster drugs in recent years. At Roche, Miro has been Global Project Leader, then Global Head of Oncology Personalized Healthcare to later becoming a senior executive within the Roche Divisional Strategy & Business Development organization, where his Team was responsible for the assessment of licensing, mergers and acquisition opportunities and deals supporting the precision medicine strategy of the company worldwide.

Miro and his Team’s activities have also been instru­mental for the Roche Diagnostics Division to embrace the digital revolution and launch products (such as the NAVIFy platform and associated SaaS products) to expand its customer base to physicians and execute upon a new diagnostic value-based business model.

Miro’s most recent role within the Roche Group has been as Chief Business Officer and Member of the Executive Committee for Foundation Medicine, a compa­ny leader in the field of next generation data-driven diagnostics for cancer patients.

Miro is a native Italian and speaks English, German and French.

<- Close

toYOU, the person at the centre

Signed agreements between employees and the company which enable employees to give life and substance to essential life projects: in the areas of training, family care and socio-cultural paths. 

 It is with pride that Sintetica, the oldest pharmaceutical company in Canton of Ticino, presents toYOU, its most recent and innovative action in the context of the human centric organisation.

Sintetica believes that important life projects undertaken by its employees should be supported by facilitating their implementation as far as possible. From this vision, which rewrites the concept of benefits, the great construction site "toYOU: the project pacts in Synthetica" was born.

toYOU promotes:

  • Advanced training (both for employees and their children);
  • Caring for seriously ill loved ones, in addition to what is already in place for one's own children;
  • Social and cultural training.


These three areas were as a holistic declination of the "manocentric" vision, an entrepreneurial and humanistic philosophy that constitutes the profound essence of this highly innovative company.

<- Close

Global Pharmaceutical CEO of the year 2020

From the United States comes an important recognition for Sintetica. The magazine Corporate America Today has awarded our CEO Augusto Mitidieri as Global Pharmaceutical CEO of the year 2020.
The Humancentric organizational model and its ability to foster innovation have impressed the panel of experts. It has also been underlined how Sintetica met the swiss and the international demand of its Intensive Care Unit‘s drugs at global level during this CV19 emergency. Once again, Sintetica nds success at international level for its true excellence: its people.
Congratulations to our CEO, heartfelt and aectionate. To all of you a big and sincere thanks for what you do every day.
<- Close

Congratulations Augusto Mitidieri, Corporate CEO

Corporate American Today awards Augusto Mitidieri, Corporate CEO, Global Pharmaceutical CEO of the Year 2020

Augusto Mitidieri - Most Influential CEO Europe 2019 for Humancentric Driven Innovation -

An internationally recognised, concrete example of scientific innovation and innovative corporate philosophy. The path undertaken by Sintetica (the oldest pharmaceutical company in Ticino), guided by its CEO Augusto Mitidieri, is not only littered with success on the global markets but is also making a name for itself with its innovative strength and ability. It is no coincidence that “Leadership by Innovation” is one of its distinguishing features.

Recently a new award, presented by CV Magazine to Augusto Mitidieri as the “Most Influential CEO Europe 2019 for Humancentric Driven Innovation”, has further confirmed the high quality of this story of courage and success.
In the interview conducted by the magazine (, Sintetica's CEO focuses on some of the cornerstones of this revolution in growth and development methods, of course, but also on the development of a different kind of corporate philosophy.
This award is a source of great satisfaction for this modern company, specialised in the production of top quality drugs for pain management and local anaesthesia.
<- Close

Le Fonti Awards 2019


Augusto Mitidieri - CEO of the Year for Sustainability in pharma industry

An innovative strategy and corporate philosophy pursued with perseverance and determination have earned Sintetica’s CEO, Augusto Mitidieri, an important new award. Le Fonti Awards have, in fact, named him "CEO of the Year for Sustainability in pharma industry" for the third year running.
Augusto Mitidieri was presented with the coveted award during a ceremony held in Milan. The official motivation behind the award, also released publically, is as follows: " For confirming himself for the third year running as the most far-sighted CEO in the pharmaceutical sector in terms of sustainability: his innovative approach to care, human resource development and a focus on the environment mean he is the one setting the benchmark at international level.
<- Close

Business Worldwide CEO Awards 2019


Augusto Mitidieri is the "Most Innovative Pharmaceutical CEO – Europe”

A new prestigious award has been assigned to the CEO of Sintetica Augusto Mitidieri, named “Most Innovative Pharmaceutical CEO – Europe” for 2019 by Business Worldwide Magazine (BWM).
Augusto Mitidieri, as the BWM press release reports, won the title outright “impressing the judges with his collaborative management strategy”.
The goal of the Business Worldwide CEO Awards 2019 is to identify and celebrate exceptional leaders from all parts of the world in various sectors.
Unlike other titles, generally focused on the company structures, the focus of the Business Worldwide CEO Awards is on the individual, their leadership abilities and the unique qualities that set them apart from the others.
By illustrating their talent and management skills, the intention is to encourage and motivate other business leaders to achieve similar goals.
Commenting on the concept of the human-centric vision on which he decided to mould Sintetica, Augusto Mitidieri told BWM:

“Passion is the real driving force behind Sintetica. And it is important for our people to be aware that they can make a dierence and help change things for the better, knowing that every action has an impact on society.
We encourage people to smile.
And a real smile is contagious. It identies Sintetica and represents the real essence of the concept of a great place to work”.

<- Close

Sintetica from Westminster to the World

Sintetica has been chosen to feature in a commemorative album marking the 70th anniversary of the Commonwealth.
Augusto Mitidieri, the man behind a veritable visionary strategy which ensures that people are the main focus when it comes to company management decisions, and Sintetica as a whole have been honored with prestigious international awards.

"I would like to share with you an honour bestowed upon our company because of the unique human-centred way Sintetica is run, which is seen as a global model for sustainability and is the foundation of our future as a successful business.


Sintetica is one of only two pharmaceutical companies, to have been chosen to feature in a commemorative album marking the 70th anniversary of the Commonwealth.

It is one of the most ambitious, authoritative and well-researched academic projects in British history.


I, personally, was interviewed by His Royal Highness Prince Charles’ biographer and royal correspondent, Robert Jobson, who asked me about the work of Sintetica and why respect, innovation and diversity are so important.


HRH Prince Charles will become head of the Commonwealth when his mother, Her Majesty, Queen Elizabeth II stands down. Prince Charles has long been a supporter of sustainability and the environment. He worked with Cambridge University to set up the Business and Sustainability Programme for business leaders and senior executives who need to make the right long-term decisions to ensure their organizations grow sustainably and profitably; which is why Prince Charles worked with the History of Parliament Trust to select the organizations chosen to be a part of this significant project in British history.


The commemorative album “The Commonwealth at 70: From Westminster to the World” includes photographs, stories and thought-provoking debate on all aspects of the states that make up the Commonwealth. It brings together best practice and offers an insight into the major Commonwealth institutions, organizations and initiatives. It shows how countries can work together for the common interests of its peoples. Business can learn from this understanding and co-operation.


I am proud of the work we do and thrilled to have received such a recognition at Westminster Abbey in London, which has one thousand years of heritage and seen many royal occasions.


Thank you for your precious support holding Sintetica up to the world as a model for success and sustainability."

Augusto Mitidieri
Corporate CEO


<- Close

Augusto Mitidieri Corporate CEO of Sintetica Awarded Best Manager of the Year

Augusto Mitidieri, CEO, has been awarded Best Manager of the Year for high achievements and professionalism in the company management.

Awarded by The Socrates Committee of Oxford this award recognises exceptional human-centric leadership and the global success of Sintetica.

This award was presented at the Socrates Award Ceremony of the Achievements Forum 2019, Institute of Directors, London.

Additionally, the Europe Business Assembly (EBA) Corporation of Social Partnership awarded Sintetica SA, Switzerland, Best Enterprise Award.
The Europe Business Assembly comprises world leaders in politics, economy, science and culture from across Europe; over 12,000 top managers from 54 countries worldwide form this global community and therefore this exclusive distinction gives broad recognition to Augusto Mitidieri, CEO, Sintetica and the Ticino region of Switzerland.

“Recognition of the exceptional global leadership of our CEO, Augusto Mitidieri, not only distinguishes an inspirational leader, it provides all of Sintetica with a huge feel good factor. Sintetica is a great place to work and feeling good about the work that we all do is in the heart of all of us.”

Speaking from London,
Darren Fergus,
Managing Director
<- Close

Most Influential CEO of the Year 2018 – Europe

The CEO of Sintetica Mendrisio has been presented with this prestigious award from CV-Magazine. “Most Influential CEO of the Year 2018 – Europe”.

This is the new and prestigious award which Corporate Vision Magazine has presented to Augusto Mitidieri, CEO of Sintetica, the oldest pharmaceutical company in the Canton of Ticino.
In presenting this award, which marks an additional milestone in the international recognition of the corporate strategy which Sintetica has been following under the leadership of its CEO, CV-Magazine focuses in particular on the elements that make up the “human-centric” philosophy which Mitidieri has brought to the operative and functional heart of the company.
To this end, the conclusion to the article/interview which CV-Magazine published in its latest issue is of note (
Augusto and the team at Sintetica will continue to deliver their exceptional services which has seen them take great strides within the industry, leading the way for others to follow. Additionally, Augusto will continue to direct his team towards success with his award-winning leadership skills, especially following his recent recognition in Corporate Vision’s 2018 Leadership Elite Awards where he was righteously awarded to accolade Most Influential CEO of the Year 2018 – Europe”.
<- Close

CV Magazine - Small Business Awards 2018

Pharmaceutical CEO of the year 2018: Augusto Mitidieri



A prestigious new addition to the list of awards won by Sintetica SA, the oldest pharmaceutical company in the Canton of Ticino, specialising in the production of top quality medicines for locoregional anaesthesiology and pain management. The firm's CEO, Augusto Mitidieri, received the European CEO Award 2018* for "Best CEO in the Pain Management Industry".
The European CEO Awards 2018 recognise the leaders who have an eye for innovation and, having firmly positioned their companies at the front of the pack, are now shaping the industries they work in.
Justification for this award includes the words:
"Mitidieri has shown a commitment to maintaining the firm's leading position within the global pharmaceuticals and pain management industry".
One of Mitidieri's main ambitions has been to implement an organisational model based on responsibility and meritocracy, rather than rigid internal hierarchies. Such an ideal falls in line with Sintetica's aim to create a working environment based on innovative ideas and positive dynamics, resulting in first-rate products that help hundreds of thousands of patients worldwide.
Most recently, Sintetica obtained marketing authorisation in the USA for its product Clorotekal, making it one of very few SMEs in the world to have registered an original pharmaceutical product in the country.
You can find an extended article from page 56 in the virtual edition of the issue here:

* European CEO is a leading subscription-based print and online publication, delivered quarterly to c-suite executives in 28 countries throughout Europe. With a network of journalists reporting to headquarters in London, European CEO provides the numbers, detailed analysis, strategy and guidance needed to make qualified business decisions in Europe's diverse marketplace.
<- Close

Business WorldWide 2018

Sintetica SA Named Europe's Pharmaceutical Company of the Year by Business Worldwide Magazine.

Swiss based pharmaceutical company Sintetica SA has another award to add to its already impressive collection, having been named 'Pharmaceutical Company of the Year - Europe' in the 2018 Brand of the Year Awards by Business Worldwide Magazine.
The 2018 Brand of the Year Awards recognize and reward organizations that have performed exceptionally over the previous 12 months, becoming dynamic forces within their industries. The judging panel look not only for businesses of world class quality, but those that strive to push boundaries, challenge perceptions and respond to global problems; earning respect from their peers and becoming employers of choice. Sintetica SA impressed the panel with its clear commitment to ongoing development, innovation and "quality without compromise" - the company's mantra.

Sintetica SA's CEO Augusto Mitidieri is leading the way in a new business model that encourages collaborative and horizontal working, combining state of the art technology with a human-centred approach. The company has come a long way since it was formed almost 100 years ago, going from a small business in Switzerland to a global company employing 300 people across 29 countries. Delivering injectable anaesthetics and analgesics to patients worldwide, the company has been the market leader in its field for many years and is now forging the way in the growing field of neuromodulation. The global division was only established in 2012, but growth is already exceeding 200% - a testament to the hard work and commitment of the CEO and his team.

Mitidieri says that the company's culture of respect has played an important role in its success. "What differentiates us from competitors is that all strategic choices are based on values of respect, a core value that permeates across every employee. It is about creating a pleasant environment in which employees can work and express themselves. When hiring new employees, we look for 'smart' people who share our thirst for diversity, our respect for traditions and our aim to be a leading global company."

This "people first" approach extends way beyond the staff team, positively affecting relationships with business partners and realizing the best possible care solutions for patients. Mitidieri's innovative new organization model, the 'Human Centered Organization', is based on the idea of responsibility and meritocracy rather than hierarchy, with managers moving from a role of command to a coaching style.

This refreshing approach certainly appears to be working. The company has recently obtained the go-ahead to market a new drug application in the United States; an outstanding achievement as one of the few small-medium sized companies in the world to register a new product in the US. It is also developing a radical new innovation in the field of post-surgery pain relief that has the potential to change the way pain is managed throughout the world.
<- Close

M&A Today Global Awards 2018

M&A Today Global Award for Excellence in Drug Development & Best for Clinic Trials 2018 - Europe

CPhI Pharma Awards - 2018

Finalist - CPhI 2018 Madrid, Spain.

ACQ5 Awards 2018

ACQ Gamechangers™ Healthcare Awards 2018.

Pasquale Mitidieri, Global markets Corporate Director, tells us more about Global Division's growth.

Le Fonti Awards 2018

Proving the Excellence of Sintetica.

Sintetica is recognised at this years Le Fonti Awards. Many world-class forces of the economy gathered over an evening event and witnessed Augusto Mitidieri being awarded for the second consecutive year the prestigious award of CEO of the Year for Corporate Social Responsibility.
For being an international force of excellence in the pharmaceutical sector, with particular reference to the treatment of pain. Thanks to its CEO's charisma and highly professional team, Sintetica has proven itself to be one of the fastest growing realities in the market and perfectly satisfies the CSR criteria.
[Le Fonti Awards]

The motivation of this acknowledgement comes from the material representation of the spirit, envisioned by Augusto Mitidieri and embodied by the entire company, with which Sintetica manages its impressive expansion on the global market, strengthened by products of the highest quality and efficiency.

The award of CEO of the Year for Corporate Social Responsibility is further acknowledgement of the excellent work Sintetica does as a whole.

<- Close

Worldwide Business Review - 2018

Sintetica S.A. - Award for Excellence in Anaesthetics & Analgesic - Switzerland Small Business Elite 2018

CV Magazine Awards - 2017

Sintetica, man at the centre

The palmarès of Sintetica SA Mendrisio, the oldest pharmaceutical company in the Canton Ticino, has been recently enriched with new important international awards.

Such acknowledgments are actually marking the pace of the Corporate’s signicant growth, which is also active in the international markets.

CV magazine has awarded once again Sintetica for the year 2017, in the small business section, as the best European pharmaceutical company. At the same time, Mr. Augusto Mitidieri, Sintetica’s CEO, earned the title of the best pharmaceutical CEO in the world. The main reason behind the attribution of the two prizes lies in the total respect as core value of Sintetica, recognized as a distinctive strategic factor in the entire pharma panorama. Likewise, in order to assure absolute excellence, Mr. Mitidieri, CEO, is now committed to building a "human-centric" corporate culture.

European Enterprise Awards - 2017

Sintetica SA - Best Pharmaceutical Company 2017 - Switzerland.

Business Worldwide’s CEO Awards 2017

Augusto Mitidieri of Sintetica is European Pharmaceutical CEO Champion.

CEO of Sintetica SA Augusto Mitidieri is a worthy recipient of the Business Worldwide Magazine award Best CEO/Pharmaceutical Industry Europe 2017.

Ultimately in charge of 230 employees spread across 25 different countries, his job is incredibly strategic, thanks to competition from emerging countries and long-term austerity measures Europe-wide. But it's not all doom and gloom for this talented CEO. That's because today there is more investment in pharmaceutical research and development than ever before.

And Mitidieri is determined that Sintetica - whom he has worked with for the past 17years – will remain a leading player within the industry. The 95-year-old company develops injectable anaesthetics and analgesics on a global scale. These are specifically used for local anaesthesia, pain management and neuromodulation. Mitidieri regards development, production and marketing as crucial areas for the company's future strategy.

Receiving his Best CEO Award from the magazine's executives, Mitidieri insisted that innovation within his industry wasn't merely about products, but also management style and organisation.

"Getting this right has been one of the key elements of our success here at Sintetica"

he declared.

Sintetica has its HQ in Switzerland, where it employs around 40 per cent of the company's total workforce. Other countries in which it has a base includes Germany, Austria, Italy and the United Kingdom.
In order for sintetica to retain its global leadership peg Mitidieri believes strategic partnering and business development are the keys to long-term growth.
"Our specialist sales teams in Switzerland, Germany, Austria, the UK and Ireland directly promote and market our products, while our Global Division delivers our top medicines through a network of strategic international worldwide partners" ex-lained Mitidieri, who is a graduate in Management Engineering from the Politecnico di Milano.
He is hardly apologetic in admitting his 'pickiness' when it comes to choosing business partners. They must share the values of Sintetica, particularly its way of prioritising people and relationships over profit.

"All our partners must meet strict ethical criteria and share our innovation-driven quality without compromising our value proposition"

said Mitidieri.
As you would expect, Sintetica is a company which regards staff as a core resource. As such Mitidieri strives to offer a creative culture and doesn't even mind risk taking too much, provided it's what he would describe as "informed".
He added:

"Making Sintetica a great place to work is our belief and is, in fact, part of our DNA."

<- Close

CPhI Pharma Awards - 2017

Finalist - CPhI 2017 Messe Frankfurt,

Worldwide Business Review - 2017

Winner of the awards Excellence in
HR - Managing Director & Vp, Human
Resource of the year 2017.

ACQ5 Awards - 2017

ACQ5 Awards - Growth Company of the year 2017.

Can respect be the key to global growth in the pharmaceutical industry?

Le Fonti Awards 2017

The prestigious Le Fonti Awards reward Sintetica’s CEO.

This is decidedly a golden period for Sintetica SA, the pharmaceutical company from Canton Ticino specialized in products for pain therapy ( The CEO Augusto Mitidieri received a prestigious award in the internationalization category for the year 2017 from the Fonti Awards (
The statement regarding Mitidieri's award is

"For his capacity to lead with foresight and attention to human resources in the context of an international specialization in injectable products for pain relief and therapy. In particular, for having invested in the education vand continuous training of the employees in terms of the global standards for Corporate social responsibility and foreign development."

the sentence was translated from Italian by Sintetica

The "Le Fonti" Awards are incorporated in the IAIR system of international awards, an event of great prominence for the business community. It reunites corporate leaders, legal offices and individuals from the highest tiers of the financial world.

This new award refines the already impressive recent prizes bestowed upon Sintetica SA as Pharmaceutical Company of the year 2016 Switzerland and upon Augusto Mitidieri as European CEO of the year 2016.

<- Close

European CEO of the year 2016

European CEO of the year 2016 Augusto Mitidieri - Sintetica.

CV Magazine - Small Business Awards 2016

Sintetica® Pharmaceutical Company of the year 2016 Switzerland.

This website contains information on products which is targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country. Please be aware that we do not take any responsibility for accessing such information which may not comply with any legal process, regulation, registration or usage in the country of your origin.